Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Sirolimus in Long COVID
NCT06960928Phase 3Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sirolimus in post-COVID-19 condition (PCC), sponsored by Icahn School of Medicine at Mount Sinai. Started Apr 2025; status: recruiting.
02
Drugs
sirolimus
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06960928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960928.